| Name | Pioglitazone |
| Description | Pioglitazone (U 72107) is a PPARγ agonist with EC50 of 0.93 and 0.99 μM on human and mouse PPARγ, respectively, and has selective and oral activity. Pioglitazone can be used in diabetes research. |
| In vitro | METHODS: HT-1080, MDA-MB-231, and PC-3 cells were treated with Pioglitazone for 3 days, and target cell toxicity was measured using MTT assay.
RESULTS: Pioglitazone did not affect cell growth at 100 μM. [1] |
| In vivo | METHODS: To investigate the effect of Pioglitazone on insulin resistance, Pioglitazone (10 and 30 mg/kg) was orally administered to ob/ob and adipo-/-ob/ob mice once daily for 14 days.
RESULTS: Pioglitazone improves insulin resistance and diabetes, which may be lipocalin-dependent in the liver but not in skeletal muscle. [2]
METHODS: To investigate the effect of Pioglitazone on cardiac remodeling, diabetic nephropathy rats were treated with oral administration of Pioglitazone (10 mg/kg) once daily for 4 weeks.
RESULTS: Pioglitazone significantly reduced body weight (BW), cardiac hypertrophy, elevated blood glucose levels, and related dyslipidemia. [3] |
| Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 28.8 mg/mL (80.8 mM), Heating is recommended.
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
|
| Keywords | U-72107 | U72107 | PPARγ | PPAR | Pioglitazone | Peroxisome proliferator-activated receptors | ligand-binding | Inhibitor | inhibit | Ferroptosis | domain | diabete | blood glucose |
| Inhibitors Related | Rosiglitazone | Daidzein | L-Glutamic acid | Sorafenib | Curcumin | Gallic Acid Monohydrate | L-Cystine | L-Glutamine | L-Glutamic acid monosodium salt | Naringenin | 2,3-Butanediol | Cisplatin |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library |
United States
